|
Fast Track to Innovation (FTI): Fast Track to Innovation (FTI) (year 2020) (Termini 3)
|
Del 27/02/2020 al 27/10/2020
|
Oberta
|
|
Ayudas para contratos predoctorales para la formación de doctores (asociados a proyectos) convocatoria 2018: Ajut complementari per al finançament d'estades a centres d'I+D i matrícula doctorat (Termini 1)
|
Del 31/12/2023 al 31/12/2023
|
Oberta
|
|
Ayudas para contratos predoctorales para la formación de doctores convocatoria 2017: Ajuts per al finançament d'estades a centres d'I+D matrícula doctorat (Termini 1)
|
Del 31/12/2021 al 31/12/2021
|
Oberta
|
|
Ayudas para contratos predoctorales para la formación de doctores convocatoria 2016: Ajuts per al finançament d'estades a centres d'I+D matrícula doctorat (Termini 1)
|
Del 31/12/2020 al 31/12/2020
|
Oberta
|
|
STRATEGIC PARTNERSHIP IN THE FIELD OF YOUTH: STRATEGIC PARTNERSHIP IN THE FIELD OF YOUTH (Termini 1)
|
Del 01/10/2020 al 01/10/2020
|
Oberta
|
|
Convocatòria del procés per a l'acreditació d'entitats TECNIO pel període 2020-2023
|
Del 15/12/2022 al 30/12/2022
|
Oberta
|
|
Convocatoria 2020 de Expresiones de interés para la financiación Extraordinaria de Proyectos de Investigació sobre el SARS-COV-2 y la enfermedad COVID-19
|
Del 31/12/2020 al 31/12/2020
|
Oberta
|
|
Convocatoria 2020 CRUE-CSIC-SANTANDER FONDO SUPERA COVID-19 de proyectos de investigación
|
Del al 18/12/2020
|
Oberta
|
|
Programa Smart Money 2020
|
Del 31/12/2020 al 31/12/2020
|
Oberta
|
|
EIC Horizon Prize for 'Innovative Batteries for eVehicles'
|
Del al 17/12/2020
|
Oberta
|
|
Ajuts per finançar projectes de recerca ?Replegar-se per créixer: l'impacte de les pandèmies en un món sense fronteres visibles? (PANDÈMIES 2020)
|
Del 26/10/2020 al 30/10/2020
|
Oberta
|
|
Returning Clinical Trial Data to study participants within a GDPR compliant and approved ethical framework (1st stage)
|
Del al 29/09/2020
|
Oberta
|
|
Returning Clinical Trial Data to study participants within a GDPR compliant and approved ethical framework (2nd stage)
|
Del al 17/03/2021
|
Oberta
|
|
Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance (1st stage)
|
Del al 29/09/2020
|
Oberta
|
|
Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance (2nd stage)
|
Del al 17/03/2021
|
Oberta
|
|
A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases (1st stage)
|
Del al 29/09/2020
|
Oberta
|
|
A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases (2nd stage)
|
Del al 17/03/2021
|
Oberta
|
|
Optimal treatment for patients with solid tumours in Europe through Artificial Intelligence (1st stage)
|
Del al 29/09/2020
|
Oberta
|
|
Optimal treatment for patients with solid tumours in Europe through Artificial Intelligence (2nd stage)
|
Del al 17/03/2021
|
Oberta
|
|
Shortening the path to Rare Disease diagnosis by using newborn genetic screening and digital technologies (1st stage)
|
Del al 29/09/2020
|
Oberta
|